Patients with PD-L1-negative squamous cell carcinoma had a 7.4-m increase in survival under dual immunotherapy, but the increase was slightly weaker with nivolumab plus chemotherapy at only 2.8 m and did not reach statistical significance.
← all excerpts
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review.
1
—
—